Search

The article offers information on toxic heavy metals, their sources, and methods to detoxify the body. Topics include common sources of exposure such as air, food, water, dental fillings, and personal care products, the health impacts of heavy metals on cellular functions and disease development, and the link between heavy metals and cancer.

A recent study conducted by the Department of Pharmacy in Putian, People's Republic of China, focused on developing a fluorescence detection method for the iron chelation therapy drug deferasirox (DEF). The study utilized N-doped blue emission carbon dots (CDs) as a fluorescent probe and demonstrated a linear relationship for DEF detection in the range of 0.5-20 μg/mL, with a low detection limit of 0.12 μg/mL. The research not only enhanced the understanding of DEF properties but also provided insights for designing CDs with specific luminescent properties for drug analysis. This study was funded by various organizations and has been peer-reviewed, offering valuable contributions to pharmaceutical research. [Extracted from the article]

A recent report from Ahmadu Bello University discusses the pathophysiology, diagnosis, and treatment advances in thalassemia, a group of inherited hematological disorders. The research highlights the genetic mutations and deletions that disrupt globin chain production, leading to anemia and associated complications. Current management strategies include blood transfusions, hydroxyurea, iron chelation therapy, and other therapeutics, with gene therapy and bone marrow transplantation showing promising curative potential. The study emphasizes the importance of early and accurate diagnoses and explores recent advancements in therapeutic approaches for thalassemia. [Extracted from the article]

A recent study conducted at Shandong University explores the potential of metal chelation therapy in effectively eliminating breast cancer and intratumor bacteria while suppressing tumor metastasis. The therapy involves a fibrous nanoagent called Zn-PEN, which depletes copper and releases zinc ions to induce tumor cell death and eradicate bacteria in breast cancer. The research suggests that this approach could offer a new therapeutic strategy for inhibiting tumor metastasis. For more information, the full article can be accessed for free at https://doi.org/10.1002/ange.202417592. [Extracted from the article]

A 1-year-old boy experienced nausea and vomiting while undergoing chelation therapy for lead poisoning caused by ingesting a lead-containing metallic medallion. The boy was initially suspected of foreign body ingestion and underwent endoscopic extraction of the medallion. Following hospitalization and outpatient chelation therapy, he faced chronic feeding issues and oral aversion due to the therapy's side effects. The presence of copper in the medallion contributed to gastrointestinal distress and iron deficiency anaemia, but the boy showed improvement in diet tolerance and developmental progress during follow-up visits. [Extracted from the article]

The patent application by Christopher Key discusses compositions and methods for treating inflammatory diseases by modulating iron transport dysregulation in cells. Iron balance is crucial for cellular health, and disruptions can lead to increased susceptibility to infectious diseases and chronic inflammatory conditions. The application proposes modifying genes related to iron metabolism and using supplemental iron removal therapies to address these issues. The goal is to reduce elevated iron levels in tissues without compromising essential cellular functions, offering potential preventive and therapeutic approaches for various health conditions. [Extracted from the article]

A study conducted at Mymensingh Medical College Hospital in Bangladesh examined the thyroid status of children with transfusion-dependent thalassemia. The researchers found that thalassemic children who did not receive chelation therapy due to financial constraints experienced iron overload in various organs, including the thyroid gland, leading to thyroid dysfunction. The study compared thalassemic children to non-thalassemic children and found that the thalassemic children had significantly lower levels of serum ferritin and higher levels of serum TSH, indicating a higher frequency of subclinical hypothyroidism. The research concluded that higher serum ferritin levels were significantly associated with the development of hypothyroidism in thalassemic patients. [Extracted from the article]

A report from the University of Memphis discusses the use of MRI technology to estimate liver iron concentration (LIC) in patients with iron overload. The report reviews different MRI-based LIC quantification techniques and provides information on MRI vendor implementations and available software for each approach. The research concludes that the R2-MRI method is the most accurate and reproducible for LIC estimation. Ongoing efforts aim to establish R2-MRI as the standard approach for quantifying LIC. [Extracted from the article]

The article focuses on a clinical trial evaluating adherence to oral chelation therapy in beta thalassemia patients. Topics include the prevalence and management of beta thalassemia; the use of different iron chelators (deferoxamine, deferiprone, deferasirox); and the impact of chelator administration routes and side effects on patient adherence.

A recent study conducted in Odisha, India, examined the prevalence of alloimmunization in pediatric thalassemia major patients. Alloimmunization refers to the development of antibodies against foreign blood cells, which can complicate transfusion therapy. The study found that 6% of the patients included in the study demonstrated the presence of one or more alloantibodies. The researchers concluded that RBC antigen typing before the first transfusion and early initiation of transfusion therapy after diagnosis are crucial in reducing alloimmunization. [Extracted from the article]

Keywords: Antidotes; Pharmaceuticals; Oxford; Europe; Hemolytic; Thalassemia; Psychosocial; Iron Overload; Psychological; United Kingdom; Quality of Life; Hydroxamic Acids; Chelation Therapy; Congenital Anemia; Hemoglobinopathies; Sickle Cell Anemia; Deferasirox Therapy; Drugs and Therapies; Health and Medicine; Risk and Prevention EN Antidotes Pharmaceuticals Oxford Europe Hemolytic Thalassemia Psychosocial Iron Overload Psychological United Kingdom Quality of Life Hydroxamic Acids Chelation Therapy Congenital Anemia Hemoglobinopathies Sickle Cell Anemia Deferasirox Therapy Drugs and Therapies Health and Medicine Risk and Prevention New research on Hematologic Diseases and Conditions - Sickle Cell Anemia is the subject of a report. Deferasirox versus deferoxamine We are uncertain whether or not deferasirox affects adherence to iron chelation therapy (three RCTs, unpooled, very low-certainty evidence), although medication adherence was high in all trials. [Extracted from the article]

Researchers from Henan University in Luoyang, China have conducted a study on the application of carbon nanomaterials in electroanalysis for the detection of illicit drugs in sports. The researchers found that electroanalytical sensors incorporating carbon nanomaterials show promise as rapid, sensitive, and cost-effective screening tools. These sensors have the potential to detect drugs at parts-per-billion levels, matching the sensitivity of immunological assays. The researchers suggest that miniaturized nanosensors can aid anti-doping enforcement through early interventions, chelation therapy, and deterrence against the proliferation of doping culture among athletes. [Extracted from the article]

A recent report discusses research on ovarian cancer conducted by Weill Cornell Medicine. The study found that iron accumulation in tumors contributes to disease progression and chemoresistance. The researchers discovered that treatment with an FDA-approved iron chelator called deferiprone can unleash innate immune responses that restrain ovarian cancer. Deferiprone reprograms cancer cells to produce type I interferon and activate natural killer cells, leading to improved survival rates in mice with ovarian cancer. This research suggests that iron chelation therapy could be a potential immunotherapeutic strategy for ovarian cancer. [Extracted from the article]

A 4-year-old boy with microcytic anaemia and congenital sideroblastic anaemia did not show improvement with iron supplementation, pyridoxine, and folic acid. Despite these treatments, his anaemia persisted, indicating a lack of efficacy. The boy then received off-label treatment with luspatercept, which resulted in a significant improvement in his anaemia. This case highlights the potential benefits of luspatercept in managing anaemia in certain cases. [Extracted from the article]

A study conducted by researchers at Cairo University found that restrictive lung disease is common among children with ss-thalassemia, a group of hereditary blood diseases characterized by reduced or absent b-globin chain synthesis. The study included 60 patients with ss-thalassemia and assessed their pulmonary functions using spirometry and impulse oscillometry. The results showed that 50% of the patients had a restrictive pattern in spirometry, and poor compliance to chelation therapy was associated with a restrictive pattern. The researchers concluded that compliance to adequate chelation therapy can decrease the incidence of pulmonary dysfunction in children with ss-thalassemia. [Extracted from the article]

A 38-year-old woman experienced severe toxic effects and acute liver failure after intentionally overdosing on ferrous-sulfate in a suicide attempt. She received various treatments, including charcoal, deferoxamine, flumazenil, acetylcysteine, and norepinephrine, but did not respond well to them. Eventually, she underwent a liver transplant and experienced clinical improvement. At the 6-month follow-up, she had no further complications. [Extracted from the article]

A 13-year-old boy developed slipped capital femoral epiphysis, nail discoloration, and nail brittleness while being treated with erdafitinib for optic pathway/hypothalamic glioma. He initially presented with emesis and headaches and was diagnosed with the glioma. After starting erdafitinib treatment, he experienced adverse reactions including nail discoloration and brittleness. He also developed hyperphosphatemia and intermittent pain in his right leg, which progressed to limping and difficulty walking. The boy was eventually diagnosed with slipped capital femoral epiphysis and underwent surgery. His tumor size decreased after the surgery and he remained stable. [Extracted from the article]

Researchers from Sun Yat-Sen University in Guangzhou, China have discovered that copper chelation therapy, specifically the use of the copper chelator Tetrathiomolybdate (TTM), can attenuate inflammation in periodontitis. The study found that TTM inhibits a newly identified form of cell death called cuproptosis, which is dependent on copper. TTM treatment also enhances autophagy and mitophagy, counteracting the inhibition of autophagy caused by lipopolysaccharide (LPS) stimulation. Additionally, TTM reduces cuproptosis, enhances autophagy flux, and decreases cathepsin B levels in mice with periodontitis. The researchers suggest that TTM could be a promising approach to alleviate macrophage dysfunction and intervene in periodontitis. [Extracted from the article]

A recent study conducted by researchers from Columbia University examined the baseline characteristics of participants in the Trial to Assess Chelation Therapy 2 (TACT2), a trial focused on patients with diabetes and prior myocardial infarction. The study aimed to determine whether chelation therapy, specifically the use of edetate disodium (EDTA) to chelate toxic metals, could reduce cardiovascular disease (CVD) events in this high-risk population. The researchers found that the participants in TACT2 had similar baseline metal levels as the general US population and were characterized by high use of medication to treat CVD and diabetes. The study concluded that TACT2 will provide valuable insights into the potential benefits of chelation therapy in reducing subsequent CVD events. [Extracted from the article]

A recent study conducted at the American University of Beirut Medical Center in Lebanon evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets in pediatric patients with iron overload. The study included 224 patients, mostly with beta-thalassemia major, who were randomized to receive either the granules or the tablets. The primary analysis found that there were no significant differences in compliance or change from baseline in serum ferritin between the two formulations. The safety profile of both formulations was comparable and consistent with the general safety profile of deferasirox. [Extracted from the article]

New tests on Ludwig van Beethoven's hair have revealed that his deafness and poor health were likely caused by lead poisoning. The German composer suffered from gastrointestinal problems, liver disease, and adult-onset hearing loss that progressed to deafness by age 30. Researchers analyzed two locks of his hair and found that they contained 64 and 95 times the normal amount of lead, enough to cause serious illness. It is believed that Beethoven's consumption of cheap wine, which was sweetened with lead acetate, may have been the cause of his lead poisoning. [Extracted from the article]

A recent study presented at the American College of Cardiology's Annual Scientific Session found that chelation therapy, a treatment that removes toxic metals from the body, did not improve outcomes for people with diabetes who had suffered a heart attack. The study, called TACT2, aimed to replicate the results of a previous trial that suggested chelation reduced cardiovascular events after a heart attack. However, the TACT2 results did not show any difference in outcomes between those who received chelation therapy and those who received a placebo. The study's lead author, Gervasio A. Lamas, stated that chelation therapy is not effective as a therapy for post-heart attack patients in the U.S. and Canada. While the study's findings may not be relevant to these countries, they could be relevant to areas of the world where lead exposure is more common. [Extracted from the article]

A 65-year-old woman with a history of transfusion-dependent myelodysplastic syndrome and neuroendocrine gastric tumor experienced a lack of efficacy during treatment with deferasirox as iron chelation therapy. Despite being on deferasirox, cardiac MRI indicated cardiac haemochromatosis. An endomyocardial biopsy revealed sarcoplasmic iron deposition with mild interstitial fibrosis. The woman's hospital stay was complicated by pericarditis, but she eventually received guideline-directed heart failure therapy and was discharged while continuing deferasirox treatment. [Extracted from the article]

A study conducted at RG Kar Medical College in West Bengal, India, focused on the impact of beta thalassemia on pubertal development in girls and the effectiveness of chelation therapy in treating the condition. Beta thalassemia is a hereditary disorder that affects endocrine function during puberty due to the excessive deposition of iron in vital organs. The study involved 300 diagnosed cases of beta thalassemia major in girls aged 13 to 17 years. Results showed that pubertal development failure is common in girls with beta thalassemia, but adequate chelation therapy led to positive outcomes in terms of hormone levels. [Extracted from the article]

Researchers at the University of Connecticut have developed a safer chelation therapy for the treatment of metallosis related to arthroplasty. Metallosis occurs when cobalt ions are released from cobalt-containing prosthetics used in hip replacements, leading to toxic effects in the body. The researchers designed a chelator called BAL-HA, which effectively binds cobalt ions and enhances their clearance from the body. This noninvasive therapy has the potential to mitigate cobalt toxicity and reduce the need for revision surgeries. [Extracted from the article]

A recent study conducted by the University of Rome Tor Vergata has identified a rare form of congenital erythrocytosis caused by SLC30A10 biallelic variants. This metabolic disorder, known as hypermanganesemia with dystonia 1 (HMNDYT1), is characterized by high levels of manganese in the blood, congenital erythrocytosis, and neurodegeneration. The researchers treated a 3-year-old boy with iron supplementation and chelation therapy, resulting in a significant reduction of blood manganese levels and erythrocytosis indexes. The study emphasizes the importance of assessing serum manganese levels in patients with unexplained polycythemia and increased liver enzymes, as well as the value of extended genetic testing for diagnosing rare genetic forms of congenital erythrocytosis. [Extracted from the article]

A recent study conducted in Babylon, Iraq, assessed the adherence to iron chelation therapy in patients with thalassemia major. Thalassemia is a severe public health problem in Iraq, and the majority of patients receive iron chelation therapy along with routine blood transfusions. The study found that the patients in Babylon had a good level of adherence to chelation therapy, although there were logistic issues that hindered the effectiveness of the treatment. The research suggests that despite the challenges, the adherence rates in Babylon were comparable to or even better than those in other Middle Eastern countries. [Extracted from the article]

A recent study conducted by researchers at the Institute of Mother and Child in Warsaw, Poland, has explored the effects of severe hemolytic disease of the newborn (HDFN) on liver function and coagulation disorders. The study focused on a female neonate who underwent chelation therapy, which resulted in positive outcomes. The patient experienced liver dysfunction, coagulation disorders, cholestasis, and anemia, which were successfully treated with transfusions and other interventions. The research concludes that appropriate treatment for severe HDFN can lead to positive outcomes without long-term consequences. [Extracted from the article]

A recent study conducted by the Department of Small Animal Medicine and Surgery has found that D-penicillamine, a commonly used chelation therapy in dogs with copper-associated hepatitis, can lead to neutropenia, a condition characterized by low levels of neutrophils in the blood. Neutropenia was observed in a Doberman Pinscher four months after starting D-penicillamine therapy, and the condition resolved after discontinuation of the treatment. The researchers recommend periodic monitoring of neutrophil counts in dogs undergoing D-penicillamine treatment. This study highlights the need for caution when using D-penicillamine in dogs with copper-associated hepatitis. [Extracted from the article]

A post hoc analysis of a clinical trial called the FIRST study found that three patients developed various toxicities after receiving deferiprone as iron chelation therapy. The toxicities included agranulocytosis, neutropenia, hepatic sequestration, hypersplenism, bacterial arthritis, and fulminant hepatitis. The study did not provide information about the patients' ages or genders, nor did it specify the dosages of deferiprone or the outcomes of the toxicities. [Extracted from the article]

A recent study conducted at Antwerp University Hospital in Belgium evaluated the efficacy and cost-effectiveness of erythrocytapheresis, a method for red blood cell exchange, in managing iron overload in children and young adults with sickle cell disease (SCD) and beta thalassemia major. The study found that erythrocytapheresis resulted in a significant decrease in serum ferritin levels while maintaining steady hemoglobin levels, compared to oral iron chelation therapy alone. The researchers concluded that erythrocytapheresis could be a financially viable treatment option for children and young adults with these conditions, and further studies are needed to optimize its use in children and expand the findings to a larger population. [Extracted from the article]

A study conducted by the Larner College of Medicine at the University of Vermont provides new insights into the utilization patterns and outcomes of iron chelation therapy (ICT) in elderly patients with low-risk myelodysplastic syndrome (LR-MDS). The study analyzed data from 2,564 LR-MDS patients and found that only 15.3% of eligible patients received ICT. Patients who received ICT had fewer transfusions, improved overall survival, lower risk of progression to acute myeloid leukemia, and fewer adverse cardiac outcomes. The study suggests that ICT may be beneficial for LR-MDS patients and further research is needed to understand its effects on molecular and clonal dynamics. [Extracted from the article]

A report from Willis Knighton Health System provides new insights into lead poisoning caused by retained bullet fragments in soft tissue. The research highlights the difficulty in ascertaining the full extent of adult lead poisoning due to limited data, but suggests that it remains an important environmental and public health problem. The prevalence of elevated lead levels is decreasing in the United States, but the consequences of lead exposure can be reduced by recognizing early symptoms, taking an occupational and environmental health history, and checking blood lead levels for diagnosis and treatment. The report also discusses the symptoms, diagnosis, and management of lead poisoning, emphasizing the importance of surveillance and chelation therapy for patients with high blood lead levels. [Extracted from the article]

A recent study on chelation therapy has provided new findings on the selection and dosage of drugs for optimal therapeutic outcomes. The study emphasizes the importance of personalized medicine parameters and the design of clinical protocols in treating diseases associated with excess iron deposition (EID) toxicity. The research highlights the positive outcomes of using higher doses of oral deferiprone (L1) in treating thalassemia major (TM) and achieving the elimination of EID. However, the study also acknowledges the drawbacks of chelation therapy, including drug toxicity and the use of suboptimal protocols. The research concludes that effective drug selection and identification of optimal dose protocols are crucial for positive therapeutic outcomes in chelation therapy. [Extracted from the article]

A 25-year-old man developed mercury poisoning after receiving an injection of mercury for tinea cruris. He experienced symptoms such as fatigue, dry cough, and nausea. Physical examination revealed conjunctival pallor, and laboratory tests showed low hemoglobin levels and high levels of mercury in his blood and urine. Chest and abdominal radiographs showed metallic opacities in various organs. The man was treated with unithiol and chelation therapy, which improved his symptoms and reduced his mercury levels. [Extracted from the article]

A recent report from the Los Alamos National Laboratory (LANL) discusses the analysis of bioassay data collected from a worker who received delayed chelation therapy following a plutonium-238 inhalation incident. The worker was treated with Ca-DTPA through intravenous injections and nebulizations over a four-year period. The study supports the hypothesis that the efficacy of the treatment is mainly due to chelation of cell-internalized plutonium by Ca-DTPA. The research concludes that the previously established chelation model is valid, although the calculation of the "true" committed effective dose was not possible. For more information, readers can refer to the article "Chelation Modeling of a Plutonium-238 Inhalation Incident Treated with Delayed DTPA" in Radiation Research. [Extracted from the article]

The article presents a discussion on the use of chelation in treating human diseases. Chelating agents are molecules that are capable of seizing and holding metal ions in a clawlike structure. Some of the well-known natural chelates include hemoglobin, chlorophyll, vitamin B-12, and the enzyme cytochrome oxidase.

The article warns about the deceptive and misleading claims made by products and therapies that claim to cure or treat autism. It emphasizes that there is no cure for autism and that many of these products may carry significant health risks. The Food and Drug Administration (FDA) plays a crucial role in warning companies against making improper claims about their products. The article provides information about autism, its symptoms, and the importance of early intervention. It also highlights FDA-approved drugs that can help manage related symptoms of autism. The FDA has cracked down on false claims made by companies, including chelation therapies, hyperbaric oxygen therapy, detoxifying clay baths, and various other products. The article provides tips to identify false or misleading claims and encourages individuals to consult healthcare professionals for accurate information and treatment options. [Extracted from the article]

In addition to drug-specific differences in the magnitude of the ferritin response, simulation scenarios indicate that ferritin elimination rates depend on ferritin concentrations at baseline. Keywords: London; United Kingdom; Europe; Carrier Proteins; Chelating Agents; Chelation Therapy; Deferasirox; Deferasirox Therapy; Drugs and Therapies; Ferritins; Health and Medicine; Iron Chelating Activity; Iron-Binding Proteins; Pharmaceuticals EN London United Kingdom Europe Carrier Proteins Chelating Agents Chelation Therapy Deferasirox Deferasirox Therapy Drugs and Therapies Ferritins Health and Medicine Iron Chelating Activity Iron-Binding Proteins Pharmaceuticals 290 290 1 10/30/23 20231102 NES 231102 2023 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Drugs and Therapies - Iron Chelating Activity have been published. [Extracted from the article]

We hypothesize that chelation therapy used to treat oral peri-implantitis could reduce the excess metal ions present in the surrounding peri-implant tissues improving the outcomes of the current treatments against periimplantitis." Keywords: Stony Brook; State:New York; United States; North and Central America; Bone Research; Chelation Therapy; Dentistry; Drugs and Therapies; Health and Medicine; Pharmaceuticals; Risk and Prevention EN Stony Brook State:New York United States North and Central America Bone Research Chelation Therapy Dentistry Drugs and Therapies Health and Medicine Pharmaceuticals Risk and Prevention 2776 2776 1 10/30/23 20231030 NES 231030 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Drugs and Therapies - Chelation Therapy are discussed in a new report. [Extracted from the article]

Sao Paulo, Brazil, South America, Alanine, Amino Acids, Antineoplastics, Antioxidants, Drugs and Therapies, Health and Medicine, Mimosine Therapy, Pharmaceuticals, Protective Agents, Mimosine Keywords: Sao Paulo; Brazil; South America; Alanine; Amino Acids; Antineoplastics; Antioxidants; Drugs and Therapies; Health and Medicine; Mimosine; Mimosine Therapy; Pharmaceuticals; Protective Agents EN Sao Paulo Brazil South America Alanine Amino Acids Antineoplastics Antioxidants Drugs and Therapies Health and Medicine Mimosine Mimosine Therapy Pharmaceuticals Protective Agents 1155 1155 1 10/24/23 20231027 NES 231027 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Antioxidants have been published. [Extracted from the article]

Keywords: Blood Proteins; Carrier Proteins; Chelation Therapy; Congenital Anemia; Drugs and Therapies; Ferritins; Globins; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemoglobinopathies; Hemoglobinopathy; Hemoglobins; Hemolytic; Iron Metabolism Disorders; Iron Overload; Iron-Binding Proteins; Metabolic Diseases and Conditions; Nutritional and Metabolic Diseases and Conditions; Pediatrics; Pharmaceuticals; Proteins; Thalassemia EN Blood Proteins Carrier Proteins Chelation Therapy Congenital Anemia Drugs and Therapies Ferritins Globins Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemoglobinopathies Hemoglobinopathy Hemoglobins Hemolytic Iron Metabolism Disorders Iron Overload Iron-Binding Proteins Metabolic Diseases and Conditions Nutritional and Metabolic Diseases and Conditions Pediatrics Pharmaceuticals Proteins Thalassemia 68 68 1 10/16/23 20231019 NES 231019 2023 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Researchers detail new data in iron overload. Comparing the evolution of median serum ferritin between therapy with erythrocytapheresis and iron chelation therapy showed a statistically significant difference (p = 0.008). [Extracted from the article]

Keywords: Sydney; Australia; Australia and New Zealand; Cancer; Clinical Research; Clinical Trials and Studies; Health and Medicine; Oncology EN Sydney Australia Australia and New Zealand Cancer Clinical Research Clinical Trials and Studies Health and Medicine Oncology 370 370 1 09/11/23 20230911 NES 230911 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Cancer is now available. According to the news editors, the research concluded: "Our study suggests that copper chelation therapy represents a potentially effective therapeutic approach for targeting TGF-beta and inhibiting EMT in a diverse range of cancers.". [Extracted from the article]

Keywords: Blood Transfusion; Chelation Therapy; Congenital Anemia; Drugs and Therapies; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemoglobinopathies; Hemolytic; Medical Devices; Pharmaceuticals; Thalassemia; Transfusion Medicine EN Blood Transfusion Chelation Therapy Congenital Anemia Drugs and Therapies Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemoglobinopathies Hemolytic Medical Devices Pharmaceuticals Thalassemia Transfusion Medicine 200 200 1 09/04/23 20230908 NES 230908 2023 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in thalassemia. Blood Transfusion, Chelation Therapy, Congenital Anemia, Drugs and Therapies, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemoglobinopathies, Hemolytic, Medical Devices, Pharmaceuticals, Thalassemia, Transfusion Medicine In Pakistan, around 5000 babies are born with this deadly disease every year.¹ Besides stem cell transplant the regular blood transfusion is the only treatment for thalassemia major.". [Extracted from the article]

For more information on this research see: Chelation Therapy Associated with Antioxidant Supplementation Can Decrease Oxidative Stress and Inflammation in Multiple Sclerosis: Preliminary Results. Keywords: Antioxidants; Autoimmune Diseases and Conditions; Autoimmune Diseases and Conditions of the Nervous System; Biomarkers; CNS Demyelinating Autoimmune Disease; Chelation Therapy; Demyelinating Diseases and Conditions; Diagnostics and Screening; Drugs and Therapies; Health and Medicine; Immune System Diseases and Conditions; Inflammation; Multiple Sclerosis; Neuroimmunology; Neurology; Pharmaceuticals; Protective Agents EN Antioxidants Autoimmune Diseases and Conditions Autoimmune Diseases and Conditions of the Nervous System Biomarkers CNS Demyelinating Autoimmune Disease Chelation Therapy Demyelinating Diseases and Conditions Diagnostics and Screening Drugs and Therapies Health and Medicine Immune System Diseases and Conditions Inflammation Multiple Sclerosis Neuroimmunology Neurology Pharmaceuticals Protective Agents 1045 1045 1 07/10/23 20230714 NES 230714 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on multiple sclerosis is now available. [Extracted from the article]

Keywords: Biological Therapy; Chelating Agents; Deferasirox; Deferasirox Therapy; Diagnostics and Screening; Drugs and Therapies; Gastroenterology; Health and Medicine; Pharmaceuticals; Surgery EN Biological Therapy Chelating Agents Deferasirox Deferasirox Therapy Diagnostics and Screening Drugs and Therapies Gastroenterology Health and Medicine Pharmaceuticals Surgery 344 344 1 07/10/23 20230711 NES 230711 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Researchers detail new data in chelating agents. The diagnosis of gastrointestinal perforation was made, and the patient was prepared for an emergent diagnostic laparoscopy which revealed a duodenal perforation in the anterior aspect of the first part of the duodenum. [Extracted from the article]